An inhibitor of arachidonate 5-lipoxygenase, Nordy, induces differentiation and inhibits self-renewal of glioma stem-like cells.
Recent progress in cancer biology indicates that eradication of cancer stem cells (CSCs) is essential for more effective cancer therapy. Unfortunately, cancer stem cells such as glioma stem-like cells (GSLCs) are often resistant to either radio- or chemotherapy. Therefore, screening and development for novel therapeutic modalities against CSCs has been an important emerging field in cancer research. In this study, we report that a synthetic dl-nordihydroguaiaretic acid compound (dl-NDGA or "Nordy"), inhibited self-renewal and induced differentiation of GSLCs in vitro and in vivo. We found that Nordy inhibited an enzyme known to be involved in leukemia stem cell and leukemia progression, Alox-5, and attenuated the growth of GSLCs in vitro. Nordy reduced the GSLC pool through a decrease in the CD133(+) population and abrogated clonogenicity. Nordy appeared to exert its effect via astrocytic differentiation by up-regulation of GFAP and down-regulation of stemness related genes, rather than by inducing apoptosis of GSLCs. The growth inhibition of xenografted glioma by Nordy was more long-lasting compared with that of the akylating agent BCNU, which exhibited significant relapse on drug discontinuation resulting from an enrichment of GSLCs. Meanwhile, transient exposure to Nordy reduced tumorigenecity of GSLCs and induced differentiation of the xenografts. Taken together, we have identified Alox-5 as a novel target in GSLCs and its inhibition with Nordy exhibits therapeutic implications through inducing GSLC differentiation.
Wang
Bin
B
Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.
Yu
Shi-cang
SC
Jiang
Jian-yong
JY
Porter
Gavin Wallace
GW
Zhao
Lin-tao
LT
Wang
Zhe
Z
Tan
Hong
H
Cui
You-hong
YH
Qian
Cheng
C
Ping
Yi-fang
YF
Bian
Xiu-wu
XW
D000071916:AC133 Antigen; D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D001094:Arachidonate 5-Lipoxygenase / Q000378:metabolism*; D001253:Astrocytes / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D005260:Female; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D005910:Glioma / Q000473:pathology*; D006023:Glycoproteins / Q000378:metabolism; D018398:Homeodomain Proteins / Q000378:metabolism; D006801:Humans; D007381:Intermediate Filament Proteins / Q000378:metabolism; D019394:Ki-67 Antigen / Q000378:metabolism; D007975:Leukotriene B4 / Q000494:pharmacology; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology*; D009637:Masoprocol / Q000031:analogs & derivatives* / Q000494:pharmacology; D051379:Mice; D008819:Mice, Nude; D000071317:Nanog Homeobox Protein; D009368:Neoplasm Transplantation; D014411:Neoplastic Stem Cells / Q000201:enzymology / Q000473:pathology*; D009419:Nerve Tissue Proteins / Q000378:metabolism; D064231:Nestin; D050814:Octamer Transcription Factor-3 / Q000378:metabolism; D010455:Peptides / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D055748:SOXB1 Transcription Factors / Q000378:metabolism; D014183:Transplantation, Heterologous; D047368:Tumor Burden / Q000187:drug effects
D000071916:AC133 Antigen; D015703:Antigens, CD; D005904:Glial Fibrillary Acidic Protein; D006023:Glycoproteins; D018398:Homeodomain Proteins; D007381:Intermediate Filament Proteins; D019394:Ki-67 Antigen; D016859:Lipoxygenase Inhibitors; C486780:NANOG protein, human; C577484:NES protein, human; D000071317:Nanog Homeobox Protein; D009419:Nerve Tissue Proteins; C577485:Nes protein, mouse; D064231:Nestin; D050814:Octamer Transcription Factor-3; C494173:POU5F1 protein, human; C000606023:PROM1 protein, human; D010455:Peptides; C000606024:Prom1 protein, mouse; C527782:SOX2 protein, human; D055748:SOXB1 Transcription Factors; C510003:nordy; D007975:Leukotriene B4; D009637:Masoprocol; D001094:Arachidonate 5-Lipoxygenase; C484610:MELK protein, human; D017346:Protein Serine-Threonine Kinases
N Engl J Med. 2007 Nov 1;357(18):1841-54
17978293
Cell. 2006 Aug 25;126(4):663-76
16904174
Cancer Res. 2003 Sep 15;63(18):5821-8
14522905
Stem Cells. 2009 Jan;27(1):40-8
18948646
Mod Pathol. 2007 Oct;20(10):1061-8
17660801
Cancer Res. 2007 May 1;67(9):4010-5
17483311
Int J Cancer. 2006 Nov 15;119(10):2247-54
16921484
Stem Cells Dev. 2007 Oct;16(5):837-47
17999604
Cancer Metastasis Rev. 2007 Dec;26(3-4):503-24
17943411
Neuropathology. 2006 Apr;26(2):99-106
16708542
Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1651-8
19423540
Clin Neuropathol. 2009 Nov-Dec;28(6):445-52
19919819
Tumour Biol. 2006;27(2):59-70
16557043
Biochem Biophys Res Commun. 2006 Apr 21;342(4):1368-74
16516855
Carcinogenesis. 2006 Sep;27(9):1902-8
16632477
Clin Cancer Res. 2008 Oct 15;14(20):6525-30
18927292
Cell. 2009 Aug 21;138(4):645-659
19682730
Mol Cancer Ther. 2006 Nov;5(11):2716-26
17121918
Cancer Cell. 2008 Jan;13(1):69-80
18167341
Neurosurgery. 2006 Feb;58(2):347-54; discussion 347-54
16462489
J Biol Chem. 2007 Mar 2;282(9):6854-62
17202146
Int Immunopharmacol. 2009 Jun;9(6):701-15
19239926
Cell Stem Cell. 2008 Apr 10;2(4):333-44
18397753
Proteomics. 2008 Feb;8(3):484-94
18232056
Biochim Biophys Acta. 2009 Feb;1789(2):99-108
19022417
Cancer Lett. 2008 Jun 28;265(1):124-34
18343028
Ann Oncol. 2006 Nov;17(11):1620-4
16600978
Cell Stem Cell. 2009 Feb 6;4(2):129-40
19200802
Nat Rev Cancer. 2008 Oct;8(10):755-68
18784658
Nat Genet. 2009 Jul;41(7):783-92
19503090
Gastroenterology. 2003 Jan;124(1):57-70
12512030
Cancer Res. 2006 Aug 15;66(16):7843-8
16912155
PLoS One. 2008 Jul 09;3(7):e2637
18612434
Cancer Res. 2006 Oct 1;66(19):9339-44
16990346
Nature. 2008 Jun 19;453(7198):1072-8
18469801
Nat Genet. 2008 May;40(5):499-507
18443585
BMC Cancer. 2007 Jul 25;7:138
17651499
J Neurooncol. 2010 May;97(3):339-46
19862483